Poseida Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 330
- Market Cap
- $272.9M
- Website
- http://www.poseida.com
- Introduction
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
Global Review Highlights Clinical Trial Landscape for Relapsed Multiple Myeloma
A comprehensive review of global clinical trials for relapsed multiple myeloma (R/R MM) reveals key trends in trial locations, phases, and sponsor types.
Roche's $1.5B Acquisition of Poseida Therapeutics Highlights Cell Therapy's Potential; Arovella Therapeutics (ALA) Poised for Phase 1 Trial
Roche acquired Poseida Therapeutics for US$1.5 billion, signaling strong interest in cell therapy, particularly allogeneic approaches for blood cancers.
Poseida's Allogeneic CAR-T Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma
P-BCMA-ALLO1, an allogeneic CAR-T therapy from Poseida Therapeutics, demonstrates promising results in heavily pretreated multiple myeloma patients.
P-BCMA-ALLO1 Demonstrates Promising Efficacy and Safety in Relapsed/Refractory Multiple Myeloma
P-BCMA-ALLO1, an allogeneic CAR-T therapy, shows an 88% overall response rate in relapsed/refractory multiple myeloma patients in a phase 1/1b trial.
Roche to Acquire Poseida Therapeutics; Merck, AstraZeneca, and Novartis Report Pipeline Success
Roche will acquire Poseida Therapeutics for $1.0 billion, expanding its CAR-T therapy portfolio, targeting hematological malignancies, solid tumors, and autoimmune diseases.
CRISPR Weekly Roundup: Advancements in Gene Editing and Clinical Trials
Beam Therapeutics reported a patient death in their BEAM-101 sickle cell disease trial, likely due to the conditioning regimen.
Poseida Therapeutics Presents Promising Data on Allogeneic CAR-T Therapies for Hematologic Cancers and Solid Tumors
Poseida Therapeutics will present preclinical data on allogeneic CAR+TCR-T cells at SITC 2024, highlighting enhanced potency for targeting solid tumors.
Gene Editing Advances: Intellia, Poseida, YolTech, and KSQ Therapeutics Report Clinical Trial Updates
Intellia Therapeutics has initiated a pivotal Phase 3 trial (HAELO) of NTLA-2002 for hereditary angioedema, evaluating its ability to reduce HAE attacks through plasma kallikrein activity reduction.
Poseida's Allogeneic CAR-T Therapy P-BCMA-ALLO1 Shows High Response in Myeloma
Poseida Therapeutics reported a 91% overall response rate with P-BCMA-ALLO1 in relapsed/refractory multiple myeloma patients in an optimized lymphodepletion arm.
P-BCMA-ALLO1 Granted FDA RMAT Designation for Relapsed/Refractory Multiple Myeloma
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1 for relapsed/refractory multiple myeloma.